Previous Article | Next Article ![]()
Journal of Virology, May 2001, p. 4896-4901, Vol. 75, No. 10
Influenza Branch, Division of Viral and
Rickettsial Diseases, National Center for Infectious Diseases,
Centers for Disease Control and Prevention, Atlanta, Georgia 30333
Received 8 November 2000/Accepted 20 February 2001
Avian influenza A H9N2 viruses are widespread among domestic
poultry and were recently isolated from humans with respiratory illness
in China. Two antigenically and genetically distinct groups of H9N2
viruses (G1 and G9) are prevalent in China. To evaluate a strategy for
vaccination, we compared G1 and G9 viruses for their relative
immunogenicity and cross-protective efficacy. Infection of BALB/c mice
with representative viruses of either group protected against
subsequent challenge with the homologous or heterologous H9N2 virus in
the absence of detectable cross-reactive serum hemagglutination inhibition antibody. Mice injected intramuscularly with inactivated G1
whole virus vaccine were completely protected from challenge with
either H9N2 virus. In contrast, mice administered inactivated G9
vaccine were only partially protected against heterologous challenge
with the G1 virus. These results have implications for the development
of human vaccines against H9N2 viruses, a priority for pandemic preparedness.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4896-4901.2001
Immunity to Influenza A H9N2 Viruses Induced by
Infection and Vaccination

*
Corresponding author. Mailing address: Influenza
Branch, Mailstop G-16, DVRD, NCID, Centers for Disease Control and
Prevention, 1600 Clifton Rd., N.E., Atlanta, GA 30333. Phone: (404)
639-4966. Fax: (404) 639-2334. E-mail: JKatz{at}cdc.gov.
Present address: USDA/ARS/Southeast Poultry Research Laboratory,
Athens, GA.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»